Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Dividends Paid - Common (2021 - 2025)

Ani Pharmaceuticals' Dividends Paid - Common history spans 5 years, with the latest figure at $344000.0 for Q3 2025.

  • For Q3 2025, Dividends Paid - Common fell 15.27% year-over-year to $344000.0; the TTM value through Dec 2025 reached $1.2 million, down 28.8%, while the annual FY2025 figure was $1.2 million, 28.8% down from the prior year.
  • Dividends Paid - Common for Q3 2025 was $344000.0 at Ani Pharmaceuticals, down from $407000.0 in the prior quarter.
  • Across five years, Dividends Paid - Common topped out at $407000.0 in Q2 2022 and bottomed at $190000.0 in Q4 2021.
  • The 5-year median for Dividends Paid - Common is $406000.0 (2022), against an average of $388875.0.
  • The largest annual shift saw Dividends Paid - Common soared 114.21% in 2022 before it fell 15.27% in 2025.
  • A 5-year view of Dividends Paid - Common shows it stood at $190000.0 in 2021, then surged by 114.21% to $407000.0 in 2022, then fell by 0.25% to $406000.0 in 2023, then changed by 0.0% to $406000.0 in 2024, then decreased by 15.27% to $344000.0 in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Dividends Paid - Common are $344000.0 (Q3 2025), $407000.0 (Q2 2025), and $406000.0 (Q1 2025).